Adenocarcinoma of Prostate
11
0
3
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
9.1%
1 terminated out of 11 trials
80.0%
-6.5% vs benchmark
18%
2 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
Multimodal Machine Learning Characterization of Solid Tumors
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy
Short Course Radiotherapy for Localized Prostate Cancer
Carbon Ions Boost Followed by Pelvic Photon Radiotherapy for High Risk Prostate Cancer
Short-term High Precision Radiotherapy for Early Prostate Cancer With Concomitant Boost on the Dominant Lesion
Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy
Devel. and Eval. of an Active Surveillance Decision Aid for Men With Low or Intermediate Grade Prostate Cancer
Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial
HDR vs LDR Brachytherapy as Monotherapy in the Treatment of Localized Prostate Cancer.
Mifepristone (RU-486) in Androgen Independent Prostate Cancer